Impact of mild or moderate chronic kidney disease on the frequency of restenosis: Results from the PRESTO trial

Patricia Best, Peter B. Berger, Barry R. Davis, Cindy L. Grines, H. Mehrdad Sadeghi, Brent A. Williams, James T. Willerson, Jeffrey R. Granett, David Holmes

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The goal of this study was to determine if restenosis is increased in mild and moderate chronic kidney disease (CKD) patients after percutaneous coronary intervention (PCI). Mortality is increased in CKD after PCI. Restenosis may contribute to increased late mortality. We analyzed 11,187 patients with a creatinine >1.8 mg/dl from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial, grouped by estimated creatinine clearance (CrCl) (<60, 60 to 89, >89 ml/min). The Cox proportional hazards models investigated the association between CrCl group and death, myocardial infarction, and target vessel revascularization (TVR). Generalized estimating equation regression models determined the association between CrCl group and lesion-specific restenosis. At 30 days, there was no difference in myocardial infarction, death, or TVR between the CrCl groups. At nine months, mortality was higher in the lowest CrCl group (2.2%, 1.2%, 0.8%; p > 0.001), which was no longer significant after adjusting for confounding variables. Myocardial infarction and TVR were not different between the groups. In patients undergoing protocol follow-up angiography, restenosis (<50%) was not increased with CKD (32%, 32%, 37%; p = 0.02). Mortality nine months after PCI is mildly increased in mild or moderate CKD patients. However, restenosis is not and does not account for the increased mortality.

Original languageEnglish (US)
Pages (from-to)1786-1791
Number of pages6
JournalJournal of the American College of Cardiology
Volume44
Issue number9
DOIs
StatePublished - Nov 2 2004

Fingerprint

Chronic Renal Insufficiency
Creatinine
Percutaneous Coronary Intervention
Mortality
Myocardial Infarction
Confounding Factors (Epidemiology)
Proportional Hazards Models
tranilast
Angiography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of mild or moderate chronic kidney disease on the frequency of restenosis : Results from the PRESTO trial. / Best, Patricia; Berger, Peter B.; Davis, Barry R.; Grines, Cindy L.; Sadeghi, H. Mehrdad; Williams, Brent A.; Willerson, James T.; Granett, Jeffrey R.; Holmes, David.

In: Journal of the American College of Cardiology, Vol. 44, No. 9, 02.11.2004, p. 1786-1791.

Research output: Contribution to journalArticle

Best, Patricia ; Berger, Peter B. ; Davis, Barry R. ; Grines, Cindy L. ; Sadeghi, H. Mehrdad ; Williams, Brent A. ; Willerson, James T. ; Granett, Jeffrey R. ; Holmes, David. / Impact of mild or moderate chronic kidney disease on the frequency of restenosis : Results from the PRESTO trial. In: Journal of the American College of Cardiology. 2004 ; Vol. 44, No. 9. pp. 1786-1791.
@article{a2a8e8e45c0d45f49ffeae22ec8a22c3,
title = "Impact of mild or moderate chronic kidney disease on the frequency of restenosis: Results from the PRESTO trial",
abstract = "The goal of this study was to determine if restenosis is increased in mild and moderate chronic kidney disease (CKD) patients after percutaneous coronary intervention (PCI). Mortality is increased in CKD after PCI. Restenosis may contribute to increased late mortality. We analyzed 11,187 patients with a creatinine >1.8 mg/dl from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial, grouped by estimated creatinine clearance (CrCl) (<60, 60 to 89, >89 ml/min). The Cox proportional hazards models investigated the association between CrCl group and death, myocardial infarction, and target vessel revascularization (TVR). Generalized estimating equation regression models determined the association between CrCl group and lesion-specific restenosis. At 30 days, there was no difference in myocardial infarction, death, or TVR between the CrCl groups. At nine months, mortality was higher in the lowest CrCl group (2.2{\%}, 1.2{\%}, 0.8{\%}; p > 0.001), which was no longer significant after adjusting for confounding variables. Myocardial infarction and TVR were not different between the groups. In patients undergoing protocol follow-up angiography, restenosis (<50{\%}) was not increased with CKD (32{\%}, 32{\%}, 37{\%}; p = 0.02). Mortality nine months after PCI is mildly increased in mild or moderate CKD patients. However, restenosis is not and does not account for the increased mortality.",
author = "Patricia Best and Berger, {Peter B.} and Davis, {Barry R.} and Grines, {Cindy L.} and Sadeghi, {H. Mehrdad} and Williams, {Brent A.} and Willerson, {James T.} and Granett, {Jeffrey R.} and David Holmes",
year = "2004",
month = "11",
day = "2",
doi = "10.1016/j.jacc.2004.07.052",
language = "English (US)",
volume = "44",
pages = "1786--1791",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - Impact of mild or moderate chronic kidney disease on the frequency of restenosis

T2 - Results from the PRESTO trial

AU - Best, Patricia

AU - Berger, Peter B.

AU - Davis, Barry R.

AU - Grines, Cindy L.

AU - Sadeghi, H. Mehrdad

AU - Williams, Brent A.

AU - Willerson, James T.

AU - Granett, Jeffrey R.

AU - Holmes, David

PY - 2004/11/2

Y1 - 2004/11/2

N2 - The goal of this study was to determine if restenosis is increased in mild and moderate chronic kidney disease (CKD) patients after percutaneous coronary intervention (PCI). Mortality is increased in CKD after PCI. Restenosis may contribute to increased late mortality. We analyzed 11,187 patients with a creatinine >1.8 mg/dl from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial, grouped by estimated creatinine clearance (CrCl) (<60, 60 to 89, >89 ml/min). The Cox proportional hazards models investigated the association between CrCl group and death, myocardial infarction, and target vessel revascularization (TVR). Generalized estimating equation regression models determined the association between CrCl group and lesion-specific restenosis. At 30 days, there was no difference in myocardial infarction, death, or TVR between the CrCl groups. At nine months, mortality was higher in the lowest CrCl group (2.2%, 1.2%, 0.8%; p > 0.001), which was no longer significant after adjusting for confounding variables. Myocardial infarction and TVR were not different between the groups. In patients undergoing protocol follow-up angiography, restenosis (<50%) was not increased with CKD (32%, 32%, 37%; p = 0.02). Mortality nine months after PCI is mildly increased in mild or moderate CKD patients. However, restenosis is not and does not account for the increased mortality.

AB - The goal of this study was to determine if restenosis is increased in mild and moderate chronic kidney disease (CKD) patients after percutaneous coronary intervention (PCI). Mortality is increased in CKD after PCI. Restenosis may contribute to increased late mortality. We analyzed 11,187 patients with a creatinine >1.8 mg/dl from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial, grouped by estimated creatinine clearance (CrCl) (<60, 60 to 89, >89 ml/min). The Cox proportional hazards models investigated the association between CrCl group and death, myocardial infarction, and target vessel revascularization (TVR). Generalized estimating equation regression models determined the association between CrCl group and lesion-specific restenosis. At 30 days, there was no difference in myocardial infarction, death, or TVR between the CrCl groups. At nine months, mortality was higher in the lowest CrCl group (2.2%, 1.2%, 0.8%; p > 0.001), which was no longer significant after adjusting for confounding variables. Myocardial infarction and TVR were not different between the groups. In patients undergoing protocol follow-up angiography, restenosis (<50%) was not increased with CKD (32%, 32%, 37%; p = 0.02). Mortality nine months after PCI is mildly increased in mild or moderate CKD patients. However, restenosis is not and does not account for the increased mortality.

UR - http://www.scopus.com/inward/record.url?scp=7044222175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044222175&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2004.07.052

DO - 10.1016/j.jacc.2004.07.052

M3 - Article

C2 - 15519008

AN - SCOPUS:7044222175

VL - 44

SP - 1786

EP - 1791

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 9

ER -